August 20th, 2026
RANKL is best studied in the context of bone remodeling. Its activity, binding to the cell surface receptor RANK, is necessary for the function of the osteoclast cells that break down bone extracellular matrix. Bone tissue is in a constant state of remodeling, built up by osteoblast cells and broken down by osteoclast cells. The loss of bone mineral density that leads to osteoporosis arises from a growing age-related imbalance between osteoblast and osteoclast activity, favoring the osteoclasts. The various established therapies used to slow the progression of osteoporosis attempt to tilt that balance away from loss of bone mineral density, such as via monoclonal antibodies targeting RANKL to suppress osteoclast activity.
In today's open access paper, researchers note that RANKL inhibition extends life in progeroid mice. The details are interesting, adding to other data suggesting that RANKL has roles in aging that go beyond issues with bone tissue, such as influence on muscle aging. One would want to see a study in normally aged mice to confirm that this is the case, of course. In the broader context, it might be worth noting that another class of drug that inhibits osteoclast activity in a different way, bisphosphonates, may also act to slow aging. There is evidence for bisphosphonates to be senolytic, for example, and human data showing a survival advantage of five years in people using bisphosphonates versus the general population.
